Securian Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Securian Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$851K	Buy	14,278 +118	+0.8%	+$6.46K	0.03%	417
2026 Q1	$800K	Buy	14,160 +160	+1%	+$9.33K	0.03%	417
2025 Q4	$832K	Sell	14,000 -380	-3%	-$20.7K	0.03%	392
2025 Q3	$779K	Sell	14,380 -224	-2%	-$12.8K	0.02%	526
2025 Q2	$803K	Buy	14,604 +197	+1%	+$11.6K	0.02%	515
2025 Q1	$1.02M	Hold	14,407	–	–	0.03%	409
2024 Q4	$947K	Sell	14,407 -397	-3%	-$26.6K	0.03%	445
2024 Q3	$1.04M	Sell	14,804 -340	-2%	-$28.4K	0.03%	424
2024 Q2	$1.25M	Buy	+15,144	New	+$1.26M	0.04%	356

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Securian Asset Management's BMRN Position: Q2 2026 in Review

Securian Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 0.83% in Q2 2026, buying an estimated $6.46K and bringing the position to 14,278 shares worth $851K. The position accounts for 0.03% of the portfolio, ranked #417.

Securian Asset Management first reported a position in BMRN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.25M in Q2 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Securian Asset Management held 14,278 shares of BioMarin Pharmaceuticals worth $851K as of Q2 2026.
Securian Asset Management bought 118 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $6.46K.
BioMarin Pharmaceuticals made up 0.03% of Securian Asset Management's portfolio in Q2 2026, its #417 holding.
Securian Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Securian Asset Management's BioMarin Pharmaceuticals position peaked at $1.25M in Q2 2024.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Securian Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.